No Data
No Data
Intra-Cellular Therapies Presents Data From The CAPLYTA Adjunctive MDD Phase 3 Program At The American College Of Neuropsychopharmacology Annual Meeting; Data Shows Robust Remission And Response Efficacy Rates In Patients Taking CAPLYTA, As Well As...
Insider Sale: Chairman and CEO of $ITCI (ITCI) Sells 1,534 Shares
Intra-Cellular Therapies(ITCI.US) Officer Sells US$8.72 Million in Common Stock
Express News | Form 144 | Intra-Cellular Therapies(ITCI.US) Officer Proposes to Sell 4.34 Million in Common Stocks
Express News | Form 144 | Intra-Cellular Therapies(ITCI.US) Officer Proposes to Sell 4.37 Million in Common Stocks
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow